The European label for J&J's Darzalex has been expanded to include newly diagnosed multiple myeloma patients eligible for stem cell transplant. Supported by Phase III trial data, the antibody is projected to generate significant revenue growth by 2030.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing